21 October 2021 - BEAM Alliance

How the EU Pharmaceutical Strategy could help prevent the next pandemic

Video recordings of BEAM’s Roundtable. Discussion with EC officials and experts on the AMR initiatives of the EU Pharmaceutical Strategy.

27 September 2021 - BEAM Alliance

BEAM Alliance wants HERA to effectively support R&D in antimicrobial resistance

BEAM Alliance welcomes the HERA proposal but urges EU Member States to recognise the importance of early-stage support for Research…

17 November 2021 - BEAM Alliance

20 research, medical and pharmaceutical organizations call on G7 to step up action against antibiotic resistance

20 national and international organisations from academia, healthcare, global health and the pharmaceutical industry appealed today to G7 governments to…

24 November 2021 - BEAM Alliance

AMR: The life of innovative SMEs

WAAW 2021. We take you behind the scenes. This series of comics illustrates the life of SMEs innovating in the…

31 January 2022 - BEAM Alliance

Towards a functioning AMR market: 4 pillars for a PULL incentive in Europe

In its latest position paper, BEAM Alliance proposes 4 pillars to design an efficient PULL incentive for AMR in Europe.

24 November 2022 - BEAM Alliance

BEAM Alliance supported the Antimicrobial Resistance campaign within the Guardian and online

BEAM Alliance calls for an effective PULL mechanism to fix the AMR market failure.

BEAM News
Member News
Events

Latest news of BEAM Alliance

23 May 2023 - BEAM Alliance

BEAM’s statement on the EU Council Recommendation on AMR

The proposal examines AMR in a rather exhaustive way. It includes provisions on the need to strengthen national action plans,…

13 March 2023 - BEAM Alliance

BEAM Alliance published its reflection paper calling for a fair evaluation of the Transferable Exclusivity Extension (TEE) voucher

BEAM Alliance proposes a hybrid model, in which innovation is rewarded by a Transferable Exclusivity Extension (TEE) voucher while, in…

17 February 2023 - BEAM Alliance

EFPIA-BEAM Rejoinder to “Transferable exclusivity voucher: a flawed incentive to stimulate antibiotic innovation”, The Lancet, 9 February 2023

The article presents several additional claims, a number of which require correction.

07 December 2022 - BEAM Alliance

BEAM Alliance’s reaction to the ‘non-paper’ issued by 14 Member states on antimicrobial market incentives

BEAM Alliance calls for an open, evidence-based discussion on the best possible solutions to be implemented at the EU-level to…

24 November 2022 - BEAM Alliance

BEAM Alliance supported the Antimicrobial Resistance campaign within the Guardian and online

BEAM Alliance calls for an effective PULL mechanism to fix the AMR market failure.

21 November 2022 - BEAM Alliance

BEAM Alliance: Building the right PULL incentive for Europe

BEAM Alliance calls for an effective PULL mechanism to fix the AMR market failure.

page 1/6

Tweets by alliancebeam

View twitter feed

Latest news of BEAM Members

07 June 2023 - Spexis AG

Spexis announces the publication of promising results for a novel class of macrocyclic, peptidomimetic antibiotics in Science Advances

“We are very proud of our team to have discovered, with our partners, a novel class of macrocyclic, peptidomimetic antibiotics…

25 May 2023 - ANTABIO S.A.S

Antabio Announces First Subjects Dosed in Phase 1 Clinical Trial of MEM-ANT3310, a Highly Differentiated Antibiotic for Severe Hospital Infections

MEM-ANT3310 is a next generation antibacterial combination that has been designed to make a significant impact on the growing problem…

10 May 2023 - AdjuTec Pharma AS

AdjuTec Pharma Files Three Patents that Strengthens Commercial Potential

The company technology offers a unique mechanism of action that inactivates bacterial defence enzymes and restores bacterial sensitivity to antibiotics.

09 May 2023 - BioVersys AG

BioVersys announces first patient dosed in Phase 2 clinical trial with BV100

Moving BV100 into Phase 2 is an important next step in developing our pipeline of pathogen-focused products against the highest…

02 May 2023 - Destiny Pharma plc

Destiny Pharma and SporeGen® announce update from research collaboration under Innovate UK grant award to develop a biotherapeutic treatment (SPOR-COV®) for COVID-19 and Influenza

SPOR COV product consists of a proprietary formulation of Bacillus bacteria that is administered nasally as a spray. Importantly, this…

18 April 2023 - Spexis AG

Spexis announces closing of capital commitment of USD 4.5 million from SPRIM Global Investments (SGI) to enable initiation of ColiFin® Phase 3 study

Building upon our recently announced clinical trial partnership, we are pleased to receive this capital commitments from SGI, which will…

page 1/49

Events

06 March 2024

8th AMR Conference – Save the date!

The AMR conference is a platform for SMEs, start-ups, big pharma, academia, investors and public institutions to discuss strategies and…

06 November 2023

BIO-EUROPE 2023

BIO-Europe® is the preeminent partnering conference for the life sciences, bringing together international decision makers from the biotechnology, pharmaceutical and…

20 September 2023

ChinaBio® Partnering Forum 2023

ChinaBio® Partnering Forum is the largest and most productive life science partnering conference in China.

07 September 2023

World AMR Congress

Since 2015, the World Anti-Microbial Resistance Congress has been the go-to conference globally for all stakeholders in the AMR space…

21 June 2023

AMR – Antimicrobial Resistance Connect

Driving innovation, investment, and actionable policy to combat the silent pandemic

07 June 2023

GARDP Webinar: Project management in antimicrobial drug R&D

The Global Antibiotic Research and Development Partnership (GARDP) is a Swiss not-for-profit organization developing new treatments for drug-resistant infections that…

20 March 2023

BIO-Europe Spring 2023: Meet your next strategic partner at Europe’s largest springtime partnering event.

The annual BIO-Europe Spring® conference will bring together the life science community for global dealmaking in-person and digitally.

16 March 2023

7th AMR Conference

The AMR conference is a platform for SMEs, start-ups, big pharma, academia, investors and public institutions to discuss strategies and…

08 March 2023

BioWednesday Cambridge with tranScrip: “Lost in Translation: Smart early clinical development with the end in mind”

This BioWednesday event, led by tranScrip will discuss how investors and entrepreneurs evaluate small companies for investment. We will give…

page 1/15